加强口腔护理预防非呼吸机医院获得性肺炎:澳大利亚多中心阶梯楔形整群随机试验
HAPPEN 试验在澳大利亚 3 家医院 9 个病房开展开放队列阶梯楔形整群随机对照研究,纳入住院≥48 小时的成人患者,评估由专职研究护士实施的口腔护理强化干预(强化口腔护理与产品提供、患者与员工教育、审计反馈)能否降低非呼吸机医院获得性肺炎(NV-HAP)发生率。
核心结论
- 与常规护理相比,改善口腔护理可降低住院患者非呼吸机医院获得性肺炎发生率,为预防指南和医院感染控制政策提供新证据。
研究设计与样本
- 开放队列、阶梯楔形、整群随机试验,在澳大利亚 3 家医院 9 个病房(集群)开展,按 3 个治疗顺序简单随机分配。
- 纳入 18 岁及以上、入住试验集群的患者,结局评估限于住院至少 48 小时者;意向性分析人群共 8870 例,对照组 4523 例、干预组 4347 例。
- 干预含三部分:强化口腔护理实施与产品提供、患者与员工教育、审计与反馈,由专职研究护士执行;对照为按医院政策的常规口腔护理;数据收集者对分配序列设盲。
关键数值与推荐
- NV-HAP 按欧洲疾病预防与控制中心(ECDC)标准定义,结局依据既定定义并经病历复核判定。
- 主要结局为 NV-HAP 发生率;次要结局包括医院获得性上、下呼吸道感染和口腔感染。
临床怎么用
- 对住院成人(非机械通气)可系统化推行强化口腔护理,包括产品保障、患者与员工教育及审计反馈。
- 配置专职人员推动口腔护理落实,并以方案完成率作为过程指标监测;对呼吸道感染和口腔感染的影响尚需进一步验证。
局限性
- 研究为开放标签设计,仅数据收集者设盲;对照为常规实践,干预为多组分捆绑,难以区分各组分独立效应。
- 仅纳入 3 家澳大利亚医院 9 个病房,住院不足 48 小时者被排除,外推需谨慎;呼吸道感染与口腔感染结局置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-ventilator hospital-acquired pneumonia (NV-HAP) is among the most prevalent health-care-associated infections, yet remains under-reported, understudied, and infrequently targeted by infection prevention strategies. Oral care is considered a key preventive measure; however, there are few high-quality randomised controlled trials conducted in hospital settings. The aim of this study is to evaluate whether an enhanced oral care intervention reduces the incidence of NV-HAP. METHODS: The Hospital Acquired Pneumonia Prevention (HAPPEN) trial was an open-cohort, stepped-wedge, cluster-randomised trial conducted across three Australian hospitals. Large public or private hospitals were eligible. Simple randomisation was used to allocate nine wards (clusters) across three treatment sequences. All patients aged 18 years or older admitted to a trial cluster were eligible, with outcomes assessed for patients admitted for at least 48 h. The intervention comprised three components: enhanced delivery of oral care and provision of products, patient and staff education, and audit and feedback, delivered by dedicated research nurses. The control was usual practice-ie, oral care performed by health-care workers as per hospital policy. Primary and secondary outcomes were analysed in the intention-to-treat population. The primary outcome was NV-HAP incidence, defined according to European Centre for Disease Prevention and Control criteria. Secondary outcomes included hospital-acquired lower and upper respiratory tract infections and oral cavity infections. Outcomes were defined using established definitions and determined following a review of medical records. This study was single blinded, with data collectors masked to allocated treatment sequences. The completed trial is registered with the Australia New Zealand Clinical Trials Registry (ACTRN12624000187549). FINDINGS: The trial was conducted from June 3, 2024, to Aug 22, 2025. A total of 12 446 admitted patients were eligible to receive the intervention, 3336 of whom were excluded because they were admitted to a trial cluster for less than 48 h. A total of 8870 patients were analysed, with 4523 exposed to the control condition and 4347 exposed to the intervention condition. NV-HAP was confirmed in 78 (0·9%) of 8870 patients: 46 (1·0%) of 4523 under the control condition and 32 (0·7%) of 4347 under the intervention condition. Intervention exposure was associated with a cumulative hazard ratio of 0·40 (95% CI 0·19-0·82), representing a decrease from 1·00 to 0·41 infections per 100 admission-days at risk. Intervention exposure resulted in a cumulative hazard ratio of 1·64 (95% CI 0·61-4·39) for lower or upper respiratory tract infection, and 1·08 (0·66-1·77) for oral cavity infection. The proportion of participants who completed the oral care protocol increased from 474 (15·9%) of 2988 to 1727 (61·9%) of 2791 following intervention exposure. INTERPRETATION: This multicentre randomised controlled trial demonstrates that improving oral care reduces NV-HAP incidence among hospitalised patients, compared with usual care. Our findings provide novel and clinically important evidence to inform future prevention guidelines and hospital infection control policy. FUNDING: Medical Research Future Fund.
引用
- White NM, Russo PL, Matterson G, et al. Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia. Lancet Infect Dis. 2026. PMID: 42259325. doi:10.1016/S1473-3099(26)00235-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。